Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®) ) in previously treated patients with severe haemophilia A: interim results of the guardian(™) 2 extension trial.

Autor: Ozelo M; IHTC 'Claudio L.P. Correa', INCT do Sangue Hemocentro UNICAMP, University of Campinas, Sao Paulo, Brazil., Misgav M; National Hemophilia Center, Chaim Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel., Abdul Karim F; National Blood Centre, Kuala Lumpur, Malaysia., Lentz SR; The University of Iowa Carver College of Medicine, Iowa City, IA, USA., Martin-Salces M; Haematology Department, Hospital Universitario La Paz, Madrid, Spain., Matytsina I; Novo Nordisk A/S, Soeborg, Denmark., Saugstrup T; Novo Nordisk A/S, Soeborg, Denmark., Santagostino E; Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Maggiore Hospital Policlinico, Milan, Italy.
Jazyk: angličtina
Zdroj: Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2015 Sep; Vol. 21 (5), pp. e436-9. Date of Electronic Publication: 2015 Jun 08.
DOI: 10.1111/hae.12737
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje